Why a diabetes drug fell short of anticancer hopes
Metformin, a chemical relative of that compound, has been a top type 2 diabetes treatment in the United States since it was approved in 1994. It’s cheap—less than a dollar per dose—and readily ...
Diversified Exposure To The Weight Loss Drug Market
The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...
A Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t Celebrating
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
Medicare coverage of obesity drugs could raise federal spending by $35B through 2034 - CBO
Medicare coverage of weight loss drugs, if authorized, would increase federal spending by about $35B from 2026 to 2034, ...
The Local5d
French healthcare system won’t pay for new anti-obesity drug
New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...
BioPharma Dive6d
Scholar Rock scores with ‘surprise’ success in SMA drug study
Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.